

Protocol

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms

(80121)

(Formerly Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms)

Medical Benefit		Effective Date: 07/01/14	Next Review Date: 03/18
Preauthorization	Yes	Review Dates: 04/07, 05/08, 09/09, 09/10, 09/11, 07/12, 03/13, 03/14, 03/15, 03/16, 03/17	

Preauthorization is required and must be obtained through Case Management.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.

Populations	Interventions	Comparators	Outcomes
Individuals: • With myelodysplastic syndrome or myeloproliferative neoplasms	Interventions of interest are: • Myeloablative conditioning allogeneic hematopoietic cell transplant	Comparators of interest are: • Standard care	Relevant outcomes include: • Overall survival • Disease-specific survival • Treatment-related mortality • Treatment-related morbidity
Individuals: • With myelodysplastic syndrome or myeloproliferative neoplasms	Interventions of interest are: • Reduced-intensity conditioning allogeneic hematopoietic cell transplant	Comparators of interest are: • Standard care	Relevant outcomes include: • Overall survival • Disease-specific survival • Treatment-related mortality • Treatment-related morbidity

Description

Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) refer to a heterogeneous group of clonal hematopoietic disorders with the potential to transform into acute myelocytic leukemia. Allogeneic hematopoietic cell transplantation (allo-HCT) has been proposed as a curative treatment option for patients with these disorders.

Summary of Evidence

For individuals who have MDS and MPN who receive myeloablative conditioning allo-HCT the evidence includes case series, which are often heterogeneous in terms of diseases included. Relevant outcomes are overall survival, disease-specific survival, and treatment-related morbidity and mortality. Primarily uncontrolled, observational studies of HCT for MDS report a relatively large range of overall and progression-free survival rates, which reflect the heterogeneity in patient populations, conditioning regimens, and other factors. Reported estimates for three- to five-year overall survival of approximately 40% to 50% are typical. For HCT for MPN, data are more limited. At least one comparative study of HCT for myelofibrosis has demonstrated improved survival with HCT compared with standard therapy. HCT is at present the only potentially curative

treatment option for patients with MDS and MPN. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have MDS or MPN who receive reduced-intensity conditioning allo-HCT, the evidence includes primarily retrospective observational series. Relevant outcomes are overall survival, disease-specific survival, and treatment-related morbidity and mortality. Direct, prospective comparisons of outcomes after HCT with either myeloablative conditioning or RIC in either MDS or MPN are not available. Evidence from retrospective nonrandomized comparisons suggests that RIC may be used in patients who are older and with more comorbidities without significantly worsening overall survival. RIC appears to be associated with lower rates of nonrelapse mortality but higher cancer relapse than myeloablative HCT. HCT is at present the only potentially curative treatment option for patients with MDSs and MPN. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Policy

Myeloablative allo-HCT may be considered **medically necessary** as a treatment of

- myelodysplastic syndromes (see Policy Guidelines) or
- myeloproliferative neoplasms (see Policy Guidelines).

Reduced-intensity conditioning allo-HCT may be considered **medically necessary** as a treatment of

- myelodysplastic syndromes or
- myeloproliferative neoplasms

in patients who for medical reasons would be unable to tolerate a myeloablative conditioning regimen (see Policy Guidelines).

Myeloablative allo-HCT or reduced-intensity conditioning allo-HCT for myelodysplastic syndromes and myeloproliferative neoplasms that does not meet the criteria in the Policy Guidelines is considered **investigational**.

Policy Guidelines

Individual transplant facilities may have their own *additional* requirements or protocols that must be met in order for the patient to be eligible for a transplant at **their** facility.

The myeloid neoplasms are categorized according to criteria developed by the World Health Organization (WHO). They are risk-stratified according to the International Prognostic Scoring System (IPSS).

2008 WHO Classification Scheme for Myeloid Neoplasms

1. Acute myeloid leukemia
2. Myelodysplastic syndromes (MDS)
3. Myeloproliferative neoplasms (MPN)
 - 3.1 Chronic myelogenous leukemia
 - 3.2 Polycythemia vera
 - 3.3 Essential thrombocythemia
 - 3.4 Primary myelofibrosis

- 3.5 Chronic neutrophilic leukemia
- 3.6 Chronic eosinophilic leukemia, not otherwise categorized
- 3.7 Hypereosinophilic leukemia
- 3.8 Mast cell disease
- 3.9 MPNs, unclassifiable
- 4. MDS/MPN
 - 4.1 Chronic myelomonocytic leukemia
 - 4.2 Juvenile myelomonocytic leukemia
 - 4.3 Atypical chronic myeloid leukemia
 - 4.4 MDS/MPN, unclassifiable
- 5. Myeloid neoplasms associated with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1
 - 5.1 Myeloid neoplasms associated with PDGFRA rearrangement
 - 5.2 Myeloid neoplasms associated with PDGFRB rearrangement
 - 5.3 Myeloid neoplasms associated with FGFR1 rearrangement (8p11 myeloproliferative syndrome)

2008 WHO Classification of MDS

- 1. Refractory anemia (RA)
- 2. RA with ring sideroblasts (RARS)
- 3. Refractory cytopenia with multilineage dysplasia (RCMD)
- 4. RCMD with ring sideroblasts
- 5. RA with excess blasts 1 and 2 (RAEB 1 and 2)
- 6. del 5q syndrome
- 7. unclassified MDS

Risk Stratification of MDS

Risk stratification for MDS is performed using the IPSS (see Table 1). This system was developed after pooling data from seven previous studies that used independent, risk-based prognostic factors. The prognostic model and the scoring system were built based on blast count, degree of cytopenia, and blast percentage. Risk scores were weighted relative to their statistical power. This system is widely used to divide patients into two categories: (1) low risk and (2) high-risk groups (see Table 2). The low-risk group includes low-risk and intermediate-1 IPSS groups; treatment goals in low-risk MDS patients are to improve quality of life and achieve transfusion independence. In the high-risk group, which includes intermediate-2 and high-risk IPSS groups, treatment goals are slowing disease progression to acute myeloid leukemia (AML) and improving survival. IPSS is usually calculated on diagnosis. The role of lactate dehydrogenase, marrow fibrosis, and β_2 -microglobulin also should be considered after establishing IPSS. If elevated, the prognostic category worsens by one category change.

Table 1. International Prognostic Scoring System: Myelodysplastic Syndrome Prognostic Variables

Variable	0	0.5	1.0	1.5	2.0
Marrow blasts (%)	< 5	5-10	-	11-20	21-30
Karyotype	Good	Intermediate	Poor		
Cytopenias	0/1	2/3	-	-	-

Table 2. International Prognostic Scoring System: Myelodysplastic Syndrome Clinical Outcomes

Risk Group	Total score	Median survival, years	Time for 25% to progress to AML, years
Low	0	5.7	9.4
Intermediate-1	0.5-1.0	3.5	3.3
Intermediate-2	1.5-2.0	1.2	1.12
High	2.5 or more	0.4	0.2

AML: acute myelocytic leukemia

An updated five category IPSS has been proposed for prognosis in patients with primary MDS or secondary AML to account for chromosomal abnormalities frequently seen in MDS (Schanz et al, 2012). This system stratifies patients into five categories: very poor, poor, intermediate, good, and very good. There has been investigation into using the five category IPSS to better characterize risk in MDS.

Given the long natural history of MDS, allo-HCT is typically considered in patients with increasing numbers of blasts, signaling a possible transformation to AML. Subtypes falling into this category include refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or chronic myelomonocytic leukemia.

Patients with refractory anemia with or without ringed sideroblasts may be considered candidates for allo-HCT when chromosomal abnormalities are present or the disorder is associated with the development of significant cytopenias (e.g., neutrophils less than 500/mm³, platelets less than 20,000/mm³).

Patients with MPNs may be considered candidates for allo-HCT when there is progression to myelofibrosis or when there is evolution toward acute leukemia. In addition, allo-HCT may be considered in patients with essential thrombocythemia with an associated thrombotic or hemorrhagic disorder. The use of allo-HCT should be based on cytopenias, transfusion dependence, increasing blast percentage over 5%, and age.

Some patients for whom a conventional myeloablative allo-HCT could be curative may be candidates for RIC allo-HCT. These include those patients whose age (typically older than 60 years) or comorbidities (e.g., liver or kidney dysfunction, generalized debilitation, prior intensive chemotherapy, low Karnofsky Performance Status) preclude use of a standard myeloablative conditioning regimen. The ideal allogeneic donors are human leukocyte antigen (HLA)-identical siblings, matched at the HLA-A, B, and DR loci (six of six). Related donors mismatched at one locus are also considered suitable donors. A matched, unrelated donor identified through the National Marrow Donor Registry is typically the next option considered. Recently, there has been interest in haploidentical donors, typically a parent or a child of the patient, where usually there is sharing of only three of the six major histocompatibility antigens. Most patients will have such a donor; however, the risk of GVHD and overall morbidity of the procedure may be severe, and experience with these donors is not as extensive as that with matched donors.

Clinical input suggests RIC allo-HCT may be considered for patients as follows:

MDS

- IPSS intermediate-2 or high risk
- Red blood cell transfusion dependence
- Neutropenia

- Thrombocytopenia
- High risk cytogenetics
- Increasing blast percentage

MPN

- Cytopenias
- Transfusion dependence
- Increasing blast percentage over 5%
- Age 60-65 years.

Medicare Advantage

If a transplant is needed, we arrange to have the transplant center review and decide whether the patient is an appropriate candidate for the transplant.

Background

Hematopoietic Cell Transplantation

Hematopoietic stem cells may be obtained from the transplant recipient (autologous hematopoietic cell transplantation [HCT]) or from a donor (allo-HCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates. Although cord blood is an allogeneic source, the stem cells in it are antigenically “naive” and thus are associated with a lower incidence of rejection or graft-versus-host disease (GVHD). Cord blood is discussed in greater detail in the Placental and Umbilical Cord Blood as a Source of Stem Cells Protocol.

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HCT. However, immunologic compatibility between donor and patient is a critical factor for achieving a good outcome of allo-HCT. Compatibility is established by typing of human leukocyte antigen (HLA) using cellular, serologic, or molecular techniques. HLA refers to the tissue type expressed at the HLA-A, -B, and -DR loci on each arm of chromosome 6. Depending on the disease being treated, an acceptable donor will match the patient at all or most of the HLA loci.

Conventional Preparative Conditioning for HCT

The conventional (“classical”) practice of allo-HCT involves administration of cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without total body irradiation at doses sufficient to destroy endogenous hematopoietic capability in the recipient. The beneficial treatment effect in this procedure is due to a combination of initial eradication of malignant cells and subsequent graft-versus-malignancy (GVM) effect that develops after engraftment of allogeneic stem cells within the patient’s bone marrow space. While the slower GVM effect is considered to be the potentially curative component, it may be overwhelmed by extant disease without the use of pretransplant conditioning. However, intense conditioning regimens are limited to patients who are sufficiently fit medically to tolerate substantial adverse effects that include preengraftment opportunistic infections secondary to loss of endogenous bone marrow function and organ damage and failure caused by the cytotoxic drugs. Furthermore, in any allo-HCT, immune suppressant drugs are required to minimize graft rejection and GVHD, which also increases susceptibility of the patient to opportunistic infections.

Reduced-Intensity Conditioning for Allo-HCT

RIC refers to the pretransplant use of lower doses or less intense regimens of cytotoxic drugs or radiation than are used in conventional full-dose myeloablative (MA) conditioning treatments. The goal of RIC is to reduce disease burden and to minimize as much as possible associated treatment-related morbidity and nonrelapse mortality (NRM) in the period during which the beneficial GVM effect of allogeneic transplantation develops. Although the definition of RIC remains arbitrary, with numerous versions employed, all seek to balance the competing effects of NRM and relapse due to residual disease. RIC regimens can be viewed as a continuum in effects, from nearly totally myeloablative to minimally myeloablative with lymphoablation, with intensity tailored to specific diseases and patient condition. Patients who undergo RIC with allo-HCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full-donor chimerism, which may be supplemented with donor lymphocyte infusions to eradicate residual malignant cells. For this protocol, RIC will refer to all conditioning regimens intended to be nonmyeloablative, as opposed to fully myeloablative (conventional) regimens.

Myelodysplastic Syndromes

MDS can occur as a primary (idiopathic) disease or can be secondary to cytotoxic therapy, ionizing radiation, or other environmental insult. Chromosomal abnormalities are seen in 40% to 60% of patients, frequently involving deletions of chromosome 5 or 7, or an extra chromosome as in trisomy 8. Most MDS diagnoses occur in individuals older than age 55 to 60 years, with an age-adjusted incidence of approximately 62% among individuals older than age 70 years. Patients either succumb to disease progression to AML or to complications of pancytopenias. Patients with higher blast counts or complex cytogenetic abnormalities have a greater likelihood of progressing to AML than do other patients.

MDS Classification and Prognosis

The French-American-British (FAB) system was used to classify MDS into five subtypes as follows: (1) refractory anemia; (2) refractory anemia with ringed sideroblasts; (3) refractory anemia with excess blasts; (4) refractory anemia with excess blasts in transformation; and (5) chronic myelomonocytic leukemia. The FAB system was supplanted by that of the World Health Organization (WHO), which records the number of lineages in which dysplasia is seen (unilineage vs. multilineage), separates the 5q-syndrome, and reduces the threshold maximum blast percentage for the diagnosis of MDS from 30% to 20%.

The most commonly used prognostic scoring system for MDS is the IPSS, which groups patients into one of four prognostic categories based on the number of cytopenias, cyto-genetic profile, and the percentage of blasts in the bone marrow. This system underweights the clinical importance of severe, life-threatening neutropenia and thrombocytopenia in therapeutic decisions and does not account for the rate of change in critical parameters (e.g., peripheral blood counts or blast percentage). However, the IPSS has been useful in comparative analysis of clinical trial results and its utility confirmed at many institutions. An updated five category IPSS has been proposed for prognosis in patients with primary MDS or secondary AML to account for chromosomal abnormalities frequently seen in MDS.¹ This system stratifies patients into five categories: very poor, poor, intermediate, good, and very good. There has been investigation into using the five category IPSS to better characterize risk in MDS. A second prognostic scoring system incorporates the WHO subgroup classification that accounts for blast percentage, cytogenetics, and severity of cytopenias as assessed by transfusion requirements. The WHO classification-based Prognostic Scoring System (WPSS) uses a six-category system, which allows more precise prognostication of overall survival (OS) duration, as well as risk for progression to AML. This system, however, is not yet in widespread use in clinical trials.

MDS Treatment

Treatment of nonprogressing MDS has involved best supportive care, including red blood cell (RBC) and platelet

transfusions and antibiotics. Active therapy was given only when MDS progressed to AML or resembled AML with severe cytopenias. A diverse array of therapies are now available to treat MDS, including hematopoietic growth factors (e.g., erythropoietin, darbepoetin, granulocyte colony-stimulating factor), transcriptional-modifying therapy (e.g., U.S. Food and Drug Administration [FDA]– approved hypomethylating agents, nonapproved histone deacetylase inhibitors), immunomodulators (e.g., lenalidomide, thalidomide, antithymocyte globulin, cyclosporine A), low-dose chemotherapy (e.g., cytarabine), and allo-HCT. Given the spectrum of treatments available, the goal of therapy must be decided upfront whether it is to improve anemia; thrombocytopenia; or neutropenia, eliminate the need for RBC transfusion, achieve complete remission, or cure the disease.

Allo-HCT is the only approach with curative potential, but its use is governed by patient age, performance status, medical comorbidities, the patient's risk preference, and severity of MDS at presentation.

Chronic Myeloproliferative Neoplasms

MPN are clonal bone marrow stem cell disorders; as a group, approximately 8400 MPN are diagnosed annually in the United States. Like MDS, MPN primarily occur in older individuals, with approximately 67% reported in patients aged 60 years and older.

MPNs are characterized by the slow but relentless expansion of a clone of cells with the potential for evolution into a blast crisis similar to AML. MPN share a common stem cell–derived clonal heritage, with phenotypic diversity attributed to abnormal variations in signal transduction as the result of a spectrum of mutations that affect protein tyrosine kinases or related molecules. The unifying characteristic common to all MPN is effective clonal myeloproliferation resulting in peripheral granulocytosis, thrombocytosis, or erythrocytosis that is devoid of dyserythropoiesis, granulocytic dysplasia, or monocytosis.

MPN Classification

In 2008, the WHO classification scheme replaced the term chronic *myeloproliferative disorder* with the term *MPN*. MPNs are a subdivision of myeloid neoplasms that includes four classic disorders: chronic myeloid leukemia, polycythemia vera, essential thrombocytopenia, and primary myelofibrosis. The WHO classification also includes chronic neutrophilic leukemia, chronic eosinophilic leukemia/hypereosinophilic syndrome, mast cell disease, and MPN unclassifiable (see Policy Guidelines section).

MPN Treatment

In indolent, nonprogressing cases, therapeutic approaches are based on relief of symptoms. Supportive therapy may include prevention of thromboembolic events. Hydroxyurea may be used in cases of high-risk essential thrombocytosis and polycythemia vera, and intermediate- and high-risk primary myelofibrosis.

In November 2011, FDA approved the orally administered selective Janus kinase 1 and 2 inhibitor ruxolitinib for the treatment of intermediate- or high-risk myelofibrosis. Ruxolitinib has been associated with improved OS, spleen size, and symptoms of myelofibrosis when compared with placebo.² The COMFORT-II trial compared ruxolitinib to best available therapy in patients with intermediate- and high-risk myelofibrosis, and demonstrated improvements in spleen volume and OS.³ In a randomized trial comparing ruxolitinib to best available therapy, including antineoplastic agents, most commonly hydroxyurea, glucocorticoids, and no therapy, for myelofibrosis, Harrison et al (2012) demonstrated improvements in spleen size and quality of life, but not OS.⁴

Myeloablative allo-HCT has been considered the only potentially curative therapy, but because most patients are of advanced age with attendant comorbidities, its use is limited to those who can tolerate the often severe treatment-related adverse effects of this procedure. However, use of RIC conditioning regimens for allo-HCT has extended the potential benefits of this procedure to selected individuals with these disorders.

Regulatory Status

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation (CFR) title 21, parts 1270 and 1271. Hematopoietic stem cells are included in these regulations.

Related Protocols

Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia

Placental and Umbilical Cord Blood as a Source of Stem Cells

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

References

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. *J Clin Oncol.* Mar 10 2012; 30(8):820-829. PMID 22331955
2. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. *N Engl J Med.* Mar 1 2012; 366(9):799-807. PMID 22375971
3. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. *Blood.* Dec 12 2013; 122(25):4047-4053. PMID 24174625
4. Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. *New England Journal of Medicine.* 2012; 366(9):787-798. PMID 22375970
5. Kasner MT, Luger SM. Update on the therapy for myelodysplastic syndrome. *Am J Hematol.* Mar 2009; 84(3):177-186. PMID 19195035
6. Kindwall-Keller T, Isola LM. The evolution of hematopoietic SCT in myelodysplastic syndrome. *Bone Marrow Transplant.* Apr 2009; 43(8):597-609. PMID 19252532
7. Oliansky DM, Antin JH, Bennett JM, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. *Biol Blood Marrow Transplant.* Feb 2009; 15(2):137-172. PMID 19167676

8. Koenecke C, Gohring G, de Wreede LC, et al. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. *Haematologica*. Mar 2015; 100(3):400-408. PMID 25552702
9. Barrett AJ, Savani BN. Allogeneic stem cell transplantation for myelodysplastic syndrome. *Semin Hematol*. Jan 2008; 45(1):49-59. PMID 18179969
10. Blaise D, Vey N, Faucher C, et al. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. *Haematologica*. Apr 2007; 92(4):533-541. PMID 17488664
11. Deschler B, de Witte T, Mertelsmann R, et al. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. *Haematologica*. Nov 2006; 91(11):1513-1522. PMID 17082009
12. Huisman C, Meijer E, Petersen EJ, et al. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years. *Biol Blood Marrow Transplant*. 2008; 14(2):181-186.
13. Kroger N, Bornhauser M, Ehninger G, et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. *Ann Hematol*. Jun 2003; 82(6):336-342. PMID 12728337
14. Laport GG, Sandmaier BM, Storer BE, et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. *Biol Blood Marrow Transplant*. Feb 2008; 14(2):246-255. PMID 18215785
15. Martino R, Caballero MD, Perez-Simon JA, et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. *Blood*. Sep 15 2002; 100(6):2243-2245. PMID 12200391
16. Mesa RA. Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders. *Hematology Am Soc Hematol Educ Program*. 2007:355-362. PMID 18024651
17. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. *J Clin Oncol*. 2005; 23(36):9387-9393.
18. Valcarcel D, Martino R. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia. *Curr Opin Oncol*. Nov 2007; 19(6):660-666. PMID 17906468
19. Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. *J Clin Oncol*. 2008; 26(4):577-584.
20. Zeng W, Huang L, Meng F, et al. Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic review. *Int J Clin Exp Med*. 2014; 7(11):4357-4368. PMID 25550955
21. Aoki K, Ishikawa T, Ishiyama K, et al. Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study. *Br J Haematol*. Feb 2015; 168(3):463-466. PMID 25228239
22. Kim H, Lee JH, Joo YD, et al. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome. *Ann Hematol*. Sep 2012; 91(9):1459-1469. PMID 22526363
23. Akhtari M. When to treat myelodysplastic syndromes. *Oncology (Williston Park)*. 2011; 25(6):480-486. PMID
24. Deeg HJ, Sandmaier BM. Who is fit for allogeneic transplantation? *Blood*. Dec 2 2010; 116(23):4762-4770. PMID 20702782

25. Giralt SA, Horowitz M, Weisdorf D, et al. Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services. *J Clin Oncol*. Feb 10 2011; 29(5):566-572. PMID 21220586
26. Deeg HJ, Bartenstein M. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status. *Arch Immunol Ther Exp (Warsz)*. Feb 2012; 60(1):31-41. PMID 22143157
27. Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. *Am J Hematol*. Jul 2012; 87(7):692-701. PMID 22696212
28. Kroger N. Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. *Blood*. Jun 14 2012; 119(24):5632-5639. PMID 22504927
29. Basquiera AL, Pizzi S, Correas AG, et al. Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina. *Pediatr Blood Cancer*. Jan 2015; 62(1):153-157. PMID 25264233
30. Boehm A, Sperr WR, Kalhs P, et al. Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experience. *Wien Klin Wochenschr*. Jan 2014; 126(1-2):23-29. PMID 24249320
31. Damaj G, Mohty M, Robin M, et al. Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. *Biol Blood Marrow Transplant*. Sep 2014; 20(9):1349-1355. PMID 24838178
32. Di Stasi A, Milton DR, Poon LM, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. *Biol Blood Marrow Transplant*. Dec 2014; 20(12):1975-1981. PMID 25263628
33. Onida F, Brand R, van Biezen A, et al. Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. *Haematologica*. Oct 2014; 99(10):1582-1590. PMID 25085359
34. Oran B, Kongtim P, Popat U, et al. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. *Biol Blood Marrow Transplant*. Oct 2014; 20(10):1618-1625. PMID 24953017
35. Yoshimi A, Strahm B, Baumann I, et al. Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia. *Biol Blood Marrow Transplant*. Mar 2014; 20(3):425-429. PMID 24316460
36. Basquiera AL, Rivas MM, Remaggi G, et al. Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO). *Hematology*. Jul 6 2015. PMID 26147089
37. Symeonidis A, van Biezen A, de Wreede L, et al. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. *Br J Haematol*. Jul 26 2015. PMID 26212516
38. Pohlen M, Groth C, Sauer T, et al. Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (60 years). *Bone Marrow Transplant*. Nov 2016; 51(11):1441-1448. PMID 27295269
39. Heidenreich S, Ziagkos D, de Wreede LC, et al. Allogeneic stem cell transplantation for patients with myelodysplastic syndrome 70 years of age or older: A retrospective study of the MDS subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT. *Biol Blood Marrow Transplant*. Oct 5 2016. PMID 27720995

40. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. *J Clin Oncol*. Feb 10 2011; 29(5):573-582. PMID 21220604
41. McLornan DP, Mead AJ, Jackson G, et al. Allogeneic stem cell transplantation for myelofibrosis in 2012. *Br J Haematol*. May 2012; 157(4):413-425. PMID 22463701
42. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. *Biol Blood Marrow Transplant*. Mar 2010; 16(3):358-367. PMID 19879949
43. Gupta V, Malone AK, Hari PN, et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. *Biol Blood Marrow Transplant*. Jan 2014; 20(1):89-97. PMID 24161923
44. Kroger N, Giorgino T, Scott BL, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. *Blood*. May 21, 2015; 125(21):3347-3350; quiz 3364. PMID 25784679
45. Kroger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Blood*. Dec 17 2009; 114(26):5264-5270. PMID 19812383
46. Gupta V, Kroger N, Aschan J, et al. A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. *Bone Marrow Transplant*. Sep 2009; 44(5):317-320. PMID 19234505
47. Abelssohn J, Merup M, Birgegard G, et al. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. *Bone Marrow Transplant*. Mar 2012; 47(3):380-386. PMID 21552298
48. (NCCN) NCCN. Myelodysplastic Syndromes v1.2016. NCCN Clinical Practice Guidelines in Oncology 2016; http://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. Accessed December 23, 2015.
49. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms, Version 2.2017. https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf. Accessed December 12, 2016.
50. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. Nov 2015; 21(11):1863-1869. PMID 26256941
51. Kroger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. *Leukemia*. Nov 2015; 29(11):2126-2133. PMID 26293647